• 1
    Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415428
  • 2
    Fritzsche FR, Hasler A, Bode PK et al. Expression of histone deacetylases 1, 2 and 3 in histological subtypes of testicular germ cell tumours. Histol Histopathol 2011; 26: 15551561
  • 3
    Ozawa A, Tanji N, Kikugawa T et al. Inhibition of bladder tumour growth by histone deacetylase inhibitor. BJU Int 2010; 105: 11811186
  • 4
    Fritzsche FR, Weichert W, Röske A et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 2008; 8: 381391
  • 5
    Patra SK, Patra A, Dahiya R. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun 2001; 287: 705713
  • 6
    Patani N, Jiang WG, Newbold RF, Mokbel K. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. Anticancer Res 2011; 31: 41154125
  • 7
    Quint K, Agaimy A, Di Fazio P et al. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch 2011; 4592: 129139
  • 8
    Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007; 5: 981989
  • 9
    Welsbie DS, Xu J, Chen Y et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 2009; 69: 958966
  • 10
    Li GC, Zhang X, Pan TJ, Chen Z, Ye ZQ. Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest. Int J Urol 2006; 13: 581586
  • 11
    Jones J, Juengel E, Mickuckyte A et al. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med 2009; 13: 23762385
  • 12
    Manton KJ, Douglas ML, Netzel-Arnett S et al. Hypermethylation of the 5′ CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis. Br J Cancer 2005; 92: 760769
  • 13
    Gravina GL, Marampon F, Giusti I et al. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models. Int J Oncol 2012; 40: 711720
  • 14
    Jones J, Juengel E, Mickuckyte A et al. Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix. J Cell Mol Med 2009; 13: 23422352
  • 15
    Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther 2010; 9: 32543266
  • 16
    Hainsworth JD, Infante JR, Spigel DR, Arrowsmith ER, Boccia RV, Burris HA. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest 2011; 29: 451455
  • 17
    Bradley D, Rathkopf D, Dunn R et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 2009; 115: 55415549
  • 18
    Shen L, Ciesielski M, Ramakrishnan S et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. Plos One 2012; 7: e30815
  • 19
    Rathkopf D, Wong BY, Ross RW et al. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 2010; 66: 181189
  • 20
    Deb AA, Wilson SS, Rove KO et al. Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro. J Urol 2011; 186: 24262433
  • 21
    Ellis L, Lehet K, Ramakrishnan S et al. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression. Plos One 2011; 6: e27178
  • 22
    Mahalingam D, Medina EC, Esquivel JA 2nd et al. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res 2010; 16: 141153
  • 23
    Wang XF, Qian DZ, Ren M et al. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res 2005; 11: 35353542
  • 24
    Björkman M, Iljin K, Halonen P et al. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer 2008; 123: 27742781
  • 25
    Juengel E, Engler J, Mickuckyte A et al. Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro. BJU Int 2010; 105: 549557
  • 26
    Wedel S, Hudak L, Seibel JM et al. Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. BMC Cancer 2011; 11: 375389
  • 27
    Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T. Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells. Oncol Res 2011; 19: 217223
  • 28
    Camphausen K, Burgan W, Cerra M et al. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004; 64: 316321
  • 29
    Camphausen K, Scott T, Sproull M, Tofilon PJ. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res 2004; 10: 60666071
  • 30
    Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM. Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2005; 62: 223229
  • 31
    Konsoula Z, Cao H, Velena A, Jung M. Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity. Int J Radiat Oncol Biol Phys 2011; 79: 15411548
  • 32
    Pili R, Salumbides B, Zhao M et al. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 2012; 106: 7784
  • 33
    Fotheringham S, Epping MT, Stimson L et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 2009; 15: 5766
  • 34
    Wardley AM, Stein R, McCaffrey J et al. Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy (2010 ASCO Annual Meeting Proceedings). J Clin Oncol 2010; 28 (Suppl.): 1052
  • 35
    Butler LM, Agus DB, Scher HI et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000; 60: 51655170
  • 36
    Siu LL, Pili R, Duran I et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008; 26: 19401947
  • 37
    Schneider BJ, Kalemkerian GP, Bradley D et al. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Invest New Drugs 2012; 30: 249257
  • 38
    Munster PN, Marchion D, Thomas S et al. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 2009; 101: 10441050
  • 39
    Münster P, Marchion D, Bicaku E et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007; 25: 19791985